Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts

Blood Cancer Journal

Volumn 5, Issue , 2015, Pages

  Aliperta, R ^a   Cartellieri, M ^a,b,c   Feldmann, A ^a   Arndt, C ^a   Koristka, S ^a   Michalk, I ^b   Von Bonin, M ^d   Ehninger, A ^d,e   Bachmann, J ^b   Ehninger, G ^d   Bornhauser M ^d   Bachmann, M P ^a,b,f  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Cellex Patient Treatment GmbH   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e GEMoaB Monoclonals GmbH   (Germany)

^f CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD137 LIGAND; CD3 ANTIBODY; CD33 ANTIGEN; CD3 ANTIGEN; CD33 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLAST CELL CRISIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MESENCHYMAL STROMA CELL; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; T LYMPHOCYTE; TARGET CELL; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, SCID; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941885123     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.73     Document Type: Article

References (38)

1. Stamova S, Koristka S, Keil J, Arndt C, Feldmann A, Michalk I et al. Cancer immunotherapy by retargeting of immune effector cells via recombinant bispecific antibody constructs. Antibodies 2012; 1: 172-198.
2. Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, Wehner R et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 2011; 25: 1053-1056.
3. Feldmann A, Arndt C, Töpfer K, Stamova S, Krone F, Cartellieri M et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol 2012; 189: 3249-3259.
4. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.
5. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. Complete remission after blinatumomab-induced donor T cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011; 25: 181-184.
6. Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N et al. T cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 2006; 55: 503-514.
7. Stork R, Zettlitz KA, Müller D, Rether M, Hanisch FG, Kontermann RE. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008; 283: 7804-7812.
8. Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, Honmou O et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005; 96: 149-156.
9. Compte M, Nuñez-Prado N, Sanz L, Alvarez-Vallina L. Immunotherapeutic organoids: a new approach to cancer treatment. Biomatter 2013; 3; e-pub; doi:10.4161/biom.23897.
10. Le Blanc K, Tammik C, Götherström C, Zetterberg E, Ringdén O. HLA-expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896.
11. Götherström C, Ringdén O, Tammik C, Zetterberg E, Westgren M, Le Blanc K. Immunological properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol 2004; 190: 239-245.
12. Uccelli A, Mancardi G, Chiesa S. Is there a role for mesenchymal stem cells in autoimmune diseases? Autoimmunity 2008; 41: 592-595.
13. Ren C, Kumar S, Chanda D, Chen J, Mountz JD, Ponnazhagan S. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 2008; 26: 2332-2338.
14. Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008; 68: 9614-9623.
15. Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, Kume H et al. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 2009; 11: 373-381.
16. von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009; 43: 245-251.
17. Wehner R, Wehrum D, Bornhäuser M, Zhao S, Schäkel K, Bachmann MP et al. Mesenchymal stem cells efficiently inhibit the proinflammatory properties of 6-sulfo LacNAc dendritic cells. Haematologica 2009; 94: 1151-1156.
18. Stamova S, Feldmann A, Cartellieri M, Arndt C, Koristka S, Apel F et al. Generation of single-chain bispecific GFP fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem 2012; 423: 261-268.
19. Arndt C, Feldmann A, Koristka S, Michalk I, Cartellieri M, Stamova S et al. Redirection of immune effector cells by bispecific antibody systems for the treatment of acute myeloid leukemia. Blood 2011; 118: 663-664.
20. Arndt C, Cartellieri M, Aliperta R, Koristka S, Michalk I, Bornhäuser M et al. Enhancing the efficacy and specificity of antibody-based T cell retargeting strategies against hematological malignancies. Blood 2013; 122: 930.
21. Arndt C, von Bonin M, Cartellieri M, Feldmann A, Koristka S, Michalk I et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 2013; 27: 964-967.
22. Ehninger A, Kramer M, Röllig C, Thiede C, Bornhäuser M, von Bonin M et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J 2014; 4: e218.
23. Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, Koristka S et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia 2014; 28: 59-69.
24. Böcker W, Yin Z, Drosse I, Haasters F, Rossmann O, Wierer M et al. Introducing a single-cell-derived human mesenchymal stem cell line expressing hTERT after lentiviral gene transfer. J Cell Mol Med 2008; 12: 1347-1359.
25. Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I et al. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun 2013; 42: 105-116.
26. Cartellieri M, Koristka S, Arndt C, Feldmann A, Stamova S, von Bonin M et al. A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells. PLoS One 2014; 9: e93745.
27. Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, Schmitz M et al. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate 2011; 71: 998-1011.
28. Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol 2012; 188: 1551-1558.
29. Park K, Jang J, Irimia D, Sturgis J, Lee J, Robinson JP et al. 'Living cantilever arrays' for characterization of mass of single live cells in fluids. Lab Chip 2008; 8: 1034-1041.
30. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827.
31. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506.
32. Ménard C, Tarte K. Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Res Ther 2013; 4: 64.
33. Castro-Manrreza ME, Mayani H, Monroy-García A, Flores-Figueroa E, Chávez-Rueda K, Legorreta-Haquet V et al. Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells. Stem Cells Dev 2014; 23: 1217-1232.
34. Sun Z, Wang S, Zhao RC. The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J Hematol Oncol 2014; 7: 14.
35. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011; 34: 236-250.
36. Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep 2014; 47: 122-129.
37. Lazennec G, Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 2008; 26: 1387-1394.
38. Compte M, Blanco B, Serrano F, Cuesta AM, Sanz L, Bernad A et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007; 14: 380-388.